The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Financials and healthcare shares lift FTSE 100

Tue, 10th May 2022 16:01

May 10 (Reuters) - Britain's FTSE 100 rose on Tuesday, boosted by financials and healthcare stocks, a day after worries around recession risks, higher interest rates, and extended COVID-19 lockdowns in China triggered a bruising sell-off on the blue-chip index.

The FTSE 100 ended 0.4% higher, after falling more than 1.5% in each of the previous two sessions.

Banking stocks gained 0.3%, after declining more than 2% on Monday, while life insurers climbed 1%.

Drugmakers AstraZeneca and GlaxoSmithKline were among top gainers, while consumer staples stock Unilever rose 1.8%.

The FTSE 100 has outperformed its domestically focussed mid-cap counterpart this year due to its international make-up and as commodity stocks tracked oil and metal prices higher.

"The FTSE 100 is full of big oil, big miners, commodity giants, and those massive multinational companies. These companies like Unilever have a huge amount of pricing power, so they are able to pass costs on to the consumer," said Danni Hewson, a financial analyst at AJ Bell.

"Mid-caps don't have the same kind of power and are not as able to pass on the pain of rising costs to their consumer."

Data showed British shoppers, hit by surging inflation, cut their spending for the first time since early 2021 when the country was under a coronavirus lockdown.

After five days of heavy selling, the FTSE 250 bounced back 0.4%.

London's Heathrow increased its 2022 passenger forecast by 16% to nearly 53 million, driven by outbound holidaymakers. That helped travel and leisure stocks gain 0.3%.

Among individual movers, Renishaw Plc slid 3.2% as the engineering firm lowered its annual profit forecast over uncertainties in global trade and warned of potential disruption to its business from COVID-19 lockdowns in China.

More News
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more
21 May 2024 08:18

TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim

(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."

Read more
21 May 2024 07:52

LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident

(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.

Read more
21 May 2024 07:34

AstraZeneca lays out plans to hit $80bn in revenues by 2030

(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.

Read more
20 May 2024 11:55

LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes

(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.

Read more
20 May 2024 08:56

AstraZeneca to build $1.5-bln cancer drug plant in Singapore

Plans to build ADCs manufacturing facility in Singapore

*

Read more
20 May 2024 08:24

TOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore

(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver "highly potent cancer-killing agents".

Read more
20 May 2024 07:47

LONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles

(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with investors hopeful the Federal Reserve could soon cut US interest rates.

Read more
20 May 2024 07:22

AstraZeneca announces $1.5bn Singapore manufacturing facility

(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).

Read more
17 May 2024 22:25

Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial

May 17 (Reuters) - AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.